Type 2 & other diabetes

A Mediterranean dietary pattern intervention does not improve cardiometabolic risk but does improve quality of life and body composition in an Aotearoa New Zealand population at increased cardiometabolic risk: A randomised controlled trial

Diabetes Obes MetabPublished Randomised controlled trial

Primary result · MetSSSResult — go to the resultEstimated difference −0.05 95% CI −0.16 to 0.06

Authors' conclusion

In participants with increased cardiometabolic risk, food provision with a Mediterranean dietary pattern and a behavioural intervention did not improve metabolic risk scores but was associated with reduced weight and improved quality of life.

Study context

Population
Adults with increased cardiometabolic risk (MetSSS > 0.35), enrolled with household/whānau; mean (SD) age 49.9 (10.9) years, 62% women; Aotearoa New Zealand
Participants
200 adults
Comparison
NZ food-based Mediterranean diet (NZMedDiet) with behavioural intervention vs usual diet
  • NZMedDietn = 102
  • Controln = 98reference
Primary endpoint
Metabolic syndrome severity score (MetSSS)
Follow-up
12 weeks

Primary result

MetSSS

Estimated difference

−0.05

95% CI −0.16 to 0.06

P = 0.35

By group

NZMedDiet

0.8

mean · SD 0.5

Control

1.0

mean · SD 0.7

NZMedDietvs Control
estimated difference −0.05 (95% CI −0.16 to 0.06); P = 0.35

As reported in the abstract

Further findings

OutcomeDifference (CI)P value
Mediterranean diet score (PyrMDS)1.6 (1.1–2.1)P < 0.001
OutcomeDifference (kg) (CI)P value
Weight−1.9 (−2.0 to −0.34)P = 0.006
OutcomeEstimateP value
SF-36 quality of lifeBetween NZMedDiet and Control · improved with NZMedDietphysical component summary score difference 4.0 (95% CI 2.4–5.7)P < 0.001
SF-36 quality of lifeBetween NZMedDiet and Control · improved with NZMedDietmental component summary score difference 3.0 (95% CI 0.7–5.2)P = 0.01

SF-36 quality of life

Wellbeing (SF-36) improved across all domains

Original publication

A Mediterranean dietary pattern intervention does not improve cardiometabolic risk but does improve quality of life and body composition in an Aotearoa New Zealand population at increased cardiometabolic risk: A randomised controlled trial. Diabetes Obes Metab. Published 29 October 2024. doi:10.1111/dom.16030

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.